Current News

Contact | Print version | Send article | RSS feed

Organon and Medarex announce biotherapeutics development agreement

21 May 2007 - Organon, the human health care business unit of Akzo Nobel, and Medarex, Inc. announced that they have entered into a collaborative agreement to develop and potentially commercialize fully human antibody therapeutics for the treatment of cancer and auto-immune disorders, utilizing Medarex's UltiMAb Human Antibody Development SystemŪ and Organon's expertise in drug discovery and development.
 
Under the terms of the agreement, Organon and Medarex plan to share development and commercialization responsibilities on any antibody-based therapeutics resulting from this collaboration, and to share revenues generated from the sale of such therapeutic products. Financial terms were not disclosed.